期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 15, 期 9, 页码 1081-1092出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2015.1079130
关键词
animal models; anti-inflammatory treatments; blood-brain barrier; comorbidities; COX-2; cytokines; neurodegeneration; outcome; prognosis; refractory status epilepticus; seizures
资金
- Fondazione Monzino
- EPITARGET [602102]
- National Institute of Neurological Disorders and Stroke (NINDS) [U01 NS05158]
- NIH [R21 NS074169, P20 NS080185]
Status epilepticus (SE) is a life-threatening neurological emergency often refractory to available treatment options. It is a very heterogeneous condition in terms of clinical presentation and causes, which besides genetic, vascular and other structural causes also include CNS or severe systemic infections, sudden withdrawal from benzodiazepines or anticonvulsants and rare autoimmune etiologies. Treatment of SE is essentially based on expert opinions and antiepileptic drug treatment per se seems to have no major impact on prognosis. There is, therefore, urgent need of novel therapies that rely upon a better understanding of the basic mechanisms underlying this clinical condition. Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause; this evidence encourages reconsideration of the treatment flow in SE patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据